Published in JAMA Oncol on December 01, 2016
Prostate cancer: Genetics of mCRPC tracked in ctDNA. Nat Rev Urol (2016) 0.76
Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget (2017) 0.76
Urological cancer: Genetics of mCRPC tracked in ctDNA. Nat Rev Clin Oncol (2016) 0.76
Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci (2016) 0.76
Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Des Devel Ther (2016) 0.75
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. Eur Urol (2016) 0.75
Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer. Ann Transl Med (2016) 0.75
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol (2017) 0.75
Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect (2017) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
The evolutionary history of lethal metastatic prostate cancer. Nature (2015) 3.59
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science (2015) 3.48
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 2.87
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol (2014) 2.86
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol (2013) 2.38
Beta-catenin mutations in human prostate cancer. Cancer Res (1998) 2.37
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 2.29
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 2.12
Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med (2015) 2.01
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol (2013) 1.90
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol (2014) 1.79
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell (2014) 1.73
Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids (1994) 1.64
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun (2015) 1.49
Processing of voided urine for prostate cancer RNA biomarker analysis. Prostate (2015) 1.44
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res (2014) 1.27
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer (2014) 1.17
Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res (2015) 1.13
Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem (2013) 1.07
Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem (2014) 0.93
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol (2015) 0.93
Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med (2015) 0.93
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology (2002) 0.92
Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chem Biol (2014) 0.90
Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nat Rev Urol (2015) 0.88
Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J Biol Chem (2009) 0.88
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate (2014) 0.79
DOT1L-HES6 fusion drives androgen independent growth in prostate cancer. EMBO Mol Med (2014) 0.79
Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clin Genitourin Cancer (2015) 0.77
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clin Genitourin Cancer (2016) 0.75